Bruton’s tyrosine kinase inhibition reduces disease severity in a model of secondary progressive autoimmune demyelination

Table 3 Clinical outcomes of late therapeutic GB7208 treatment in EAE Biozzi mice

Readout	Vehicle (n = 14)	GB7208 Day 49 (n = 14)	Test statistic_(d.f.) (p value)
Balanced for enrollment
Day of onset	14.3 ± 1.4	14.1 ± 1.6	–
Score at onset	1.29 ± 0.67	1.43 ± 0.51	–
Score at enrollment	2.21 ± 0.38	2.21 ± 0.38	–
Maximum score through Day 49	3.18 ± 0.32	3.25 ± 0.26	–
Readouts of efficacy
Efficacy period maximum score	2.82 ± 0.50	2.29 ± 0.32	U = 40 (0.005)
End score	2.39 ± 0.53	1.96 ± 0.31	U = 49.5 (0.017)
Relative end body weight (%)	97.4 ± 11.6	108.2 ± 9.6	t₍₂₆₎ = 2.69 (0.012)

Analyses were performed on all mice from the experiment shown in Fig. 7e. Values are shown as mean ± SD. Percent relative end body weight is relative to body weight on Day 0. Significance for efficacy period (period starting 15 days after treatment onset, i.e., Day 64, through study termination) maximum score and end score was tested using two-tailed Mann–Whitney tests. Significance for percent relative end body weight was tested using a two-tailed unpaired t test. Bold p values indicate a significant difference vs. the Vehicle group

ISSN: 2051-5960